BridgeMD
Additive Benefits of Semaglutide for open-AngLe glaucoma – an Opportunity for Neuroprotection (ABSALON)
EU CTIS ID: 2024-518510-87-00
What this study is testing
The aim of this clinical trial is to investigate whether oral semaglutide can safely improve inner retinal function in patients with glaucoma.
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Ability to read and speak Danish
- 45 years or older at the time of inclusion
- Visual acuity equal to or above 0.5 in the study eye
- Diagnosis of primary open-angle glaucoma with mean deviation (MD) ≤ 16 dB with repeatable and reliable (false positive less than 15 %) visual field loss measured by standard automated perimetry on at least one eye
- Receiving intraocular pressure (IOP) lowering glaucoma treatment
- Nerve fiber layer defects identified by optical coherence tomography (OCT)
You likely can't join if
- Diabetes or renal impairment
- Previous history of pancreatitis
- BMI < 18.5
- Subjects receiving treatment with: Dipeptidyl peptidase–4 inhibitors, Other GLP-1RAs, Insulin, Insulin analogues, Sulfonylurea, Systemic corticosteroids, or Immunosuppressants
- Medical history of significant eye disease (including ocular trauma) other than glaucoma
- Ocular inflammation/infection within three months from inclusion
See the full eligibility criteria
- Ability to read and speak Danish
- 45 years or older at the time of inclusion
- Visual acuity equal to or above 0.5 in the study eye
- Diagnosis of primary open-angle glaucoma with mean deviation (MD) ≤ 16 dB with repeatable and reliable (false positive less than 15 %) visual field loss measured by standard automated perimetry on at least one eye
- Receiving intraocular pressure (IOP) lowering glaucoma treatment
- Nerve fiber layer defects identified by optical coherence tomography (OCT)
- Diabetes or renal impairment
- Previous history of pancreatitis
- BMI < 18.5
- Subjects receiving treatment with: Dipeptidyl peptidase–4 inhibitors, Other GLP-1RAs, Insulin, Insulin analogues, Sulfonylurea, Systemic corticosteroids, or Immunosuppressants
- Medical history of significant eye disease (including ocular trauma) other than glaucoma
- Ocular inflammation/infection within three months from inclusion
- Intraocular surgery 3 months before inclusion
- Smoker at the time of inclusion
- Pregnant or breast-feeding
- Females of childbearing potential who are not using adequate contraceptive
- Subjects allergic to drug ingredients administered during the trial
- Subjects with untreated severe systemic disease or malignancies
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.